Lercanidipină Gemax Pharma (Lercanidipine Hydrochloride)

Lercanidipine is indicated for the management of arterial hypertension, acting on the vascular smooth‑muscle calcium channels to lower blood pressure.

• Essential hypertension: reduces systolic and diastolic blood pressure in adults.
• Isolated systolic hypertension: provides effective control of elevated systolic pressure.
• Secondary hypertension (renovascular, endocrine): used as part of combination therapy to achieve target pressures.

• Lercanidipine selectively blocks L-type calcium channels in vascular smooth muscle, inhibiting calcium influx that is required for contraction. This results in arterial vasodilation, decreased peripheral vascular resistance, and consequently a reduction in systemic blood pressure without significant negative inotropic effects on the heart.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild to moderate intensity.
• Flushing: warm sensation, often on the face.
• Peripheral edema: swelling of ankles or feet.
• Dizziness or light‑headedness.
• Tachycardia: increased heart rate.
• Fatigue: general feeling of tiredness.

Serious or Rare Side Effects

• Angioedema: swelling of lips, tongue, or airway.
• Severe hypotension: marked drop in blood pressure causing syncope.
• Myocardial infarction: rare occurrence in susceptible patients.
• Hepatic injury: elevated liver enzymes or hepatitis.
• Severe allergic reaction: rash, hives, or anaphylaxis.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks.

• Blood pressure monitoring: check regularly to avoid excessive hypotension.
• Hepatic impairment: use with caution; dose adjustment may be required.
• Concomitant antihypertensives: assess for additive blood‑pressure lowering effects.
• Cardiovascular disease: evaluate for underlying ischemic heart disease.
• Pregnancy and lactation: safety not established; avoid unless clearly needed.
• Store at below 25°C: keep in the original pack, protect from moisture.

Lercanidipine can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase plasma levels.
• Grapefruit juice: may raise drug concentration.
• Other calcium‑channel blockers: additive vasodilatory effect leading to hypotension.
• Rifampicin or other CYP3A4 inducers: reduce therapeutic effect.
• Concurrent use with antihypertensive agents that cause profound hypotension.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance blood‑pressure reduction.

• Beta‑blockers: monitor heart rate and blood pressure.
• ACE inhibitors or ARBs: watch for excessive blood‑pressure lowering.
• NSAIDs: may blunt antihypertensive response.
• Lipid‑lowering agents (e.g., statins metabolized by CYP3A4): monitor for increased statin levels.